Literature DB >> 17602782

Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.

Mariko Kusaba1, Kazuhiko Nakao, Takashi Goto, Daisuke Nishimura, Hiroshi Kawashimo, Hidetaka Shibata, Yasuhide Motoyoshi, Naota Taura, Tatsuki Ichikawa, Keisuke Hamasaki, Katsumi Eguchi.   

Abstract

BACKGROUND/AIMS: Signal transducer and activator of transcription 3 (STAT3) is constitutively activated and regulates cell growth and survival of various cancer cells. We investigated the anti-tumor effect of AG490, a Janus kinase 2 specific inhibitor, inhuman hepatoma cells.
METHODS: Effects of AG490 on STAT3 activation, on cell-growth and survival, and on the expression of cell-cycle- and apoptosis-related proteins were evaluated in Huh-1, Huh-7, HepG2 and Hep3B cells. Next, whether AG490 renders hepatoma cells susceptible to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was examined in vitro and in vivo.
RESULTS: Constitutively activated STAT3 through tyrosine phosphorylation was detected in all hepatoma cells. AG490 inhibited the phosphorylation of STAT3 and its activity. AG490 induced cell cycle arrest in Huh-1, Huh-7 and HepG2 through cyclin D1 downregulation, and induced marked apoptosis in Hep3B. AG490 downregulated at least one of the anti-apoptotic proteins, Bcl-xL, survivin or XIAP in all hepatoma cells. AG490 sensitized Huh-1, Huh-7 and HepG2 to TRAIL-induced apoptosis in vitro. Intraperitoneal injection of AG490, the combination of AG490 and TRAIL more greatly, repressed the growth of subcutaneous Huh-7 tumors in athymic mice.
CONCLUSIONS: Abrogation of constitutive activation of STAT3 by AG490 enhances the anti-tumor activity of TRAIL against human hepatoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602782     DOI: 10.1016/j.jhep.2007.04.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

2.  Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway.

Authors:  Liu-Ya Tang; Mary Heller; Zhaojing Meng; Li-Rong Yu; Yi Tang; Ming Zhou; Ying E Zhang
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

3.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

4.  Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression.

Authors:  Vladimir N Ivanov; Shanaz A Ghandhi; Hongning Zhou; Sarah X Huang; Yunfei Chai; Sally A Amundson; Tom K Hei
Journal:  Exp Cell Res       Date:  2011-04-02       Impact factor: 3.905

5.  Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.

Authors:  Curtis J Henrich; Cheryl L Thomas; Alan D Brooks; Nancy Lynn Booth; Evan M Lowery; Richard J Pompei; James B McMahon; Thomas J Sayers
Journal:  Apoptosis       Date:  2012-01       Impact factor: 4.677

6.  Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction.

Authors:  Yi Jiang; Ze-Hong Miao; Lei Xu; Bing Yu; Jing-Xu Gong; Lin-Jiang Tong; Yi Chen; Zhao-Li Zhou; Hong-Chun Liu; Yi Wang; Yue-Wei Guo; Jian Ding
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

7.  Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.

Authors:  Kuen-Feng Chen; Hui-Ling Chen; Chung-Wai Shiau; Chun-Yu Liu; Pei-Yi Chu; Wei-Tien Tai; Kimihisa Ichikawa; Pei-Jer Chen; Ann-Lii Cheng
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

8.  Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Hongning Zhou; Michael A Partridge; Tom K Hei
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Germacrone induces apoptosis in human hepatoma HepG2 cells through inhibition of the JAK2/STAT3 signalling pathway.

Authors:  Yun-Yi Liu; Qian Zheng; Bin Fang; Wei Wang; Feng-Yun Ma; Sadia Roshan; Amal Banafa; Ming-Jie Chen; Jun-Li Chang; Xiao-Min Deng; Ke-Xiu Li; Guang-Xiao Yang; Guang-Yuan He
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

10.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.